Present and Future Therapeutic Approaches to Barrier Dysfunction
Fortea, Marina (Katholieke Universiteit te Leuven (1970-))
Albert-Bayo, Mercé (Vall d'Hebron Institut de Recerca (VHIR))
Abril-Gil, Mar (Vall d'Hebron Institut de Recerca (VHIR))
Ganda Mall, John-Peter (Vall d'Hebron Institut de Recerca (VHIR))
Serra Ruiz, Xavier (Hospital Universitari Vall d'Hebron)
Henao-Paez, Alejandro (Hospital Universitari Vall d'Hebron)
Expósito, Elba (Vall d'Hebron Institut de Recerca (VHIR))
González Castro, Ana Maria (Vall d'Hebron Institut de Recerca (VHIR))
Guagnozzi, Danila (Vall d'Hebron Institut de Recerca (VHIR))
Lobo Álvarez, Beatriz (Vall d'Hebron Institut de Recerca (VHIR))
Alonso Cotoner, Carmen (Vall d'Hebron Institut de Recerca (VHIR))
Santos, Javier (Vall d'Hebron Institut de Recerca (VHIR))
Universitat Autònoma de Barcelona

Data:	2021
Resum:	There is converging and increasing evidence, but also uncertainty, for the role of abnormal intestinal epithelial barrier function in the origin and development of a growing number of human gastrointestinal and extraintestinal inflammatory disorders, and their related complaints. Despite a vast literature addressing factors and mechanisms underlying changes in intestinal permeability in humans, and its connection to the appearance and severity of clinical symptoms, the ultimate link remains to be established in many cases. Accordingly, there are no directives or clinical guidelines related to the therapeutic management of intestinal permeability disorders that allow health professionals involved in the management of these patients to carry out a consensus treatment based on clinical evidence. Instead, there are multiple pseudoscientific approaches and commercial propaganda scattered on the internet that confuse those affected and health professionals and that often lack scientific rigor. Therefore, in this review we aim to shed light on the different therapeutic options, which include, among others, dietary management, nutraceuticals and medical devices, microbiota and drugs, and epigenetic and exosomes-manipulation, through an objective evaluation of the scientific publications in this field. Advances in the knowledge and management of intestinal permeability will sure enable better options of dealing with this group of common disorders to enhance quality of life of those affected.
Ajuts:	Ministerio de Sanidad y Consumo CB06/04/0021 European Commission 848228
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Epithelial barrier function ; Intestinal permeability ; Mast cell stabilizers ; Mucoprotectants ; Nutrients ; Prebiotics ; Probiotics ; Short chain fatty acids
Publicat a:	Frontiers in nutrition, Vol. 8 (october 2021) , ISSN 2296-861X

DOI: 10.3389/fnut.2021.718093
PMID: 34778332

31 p, 3.4 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats